New Cure for Deadly Visceral Leishmaniasis (Kala-Azar) Approved by Government of India

SAN FRANCISCO / NEW DELHI, India — The Institute for OneWorld Health, a nonprofit pharmaceutical company that develops medicines for neglected diseases of the developing world, today announced that the Drug-Controller General of India (DCGI) has approved Paromomycin Intramuscular (IM) Injection for the treatment of Visceral Leishmaniasis (VL), the second most deadly parasitic disease in the world following malaria.

To view the full press release, visit The Institute for OneWorld Health Web site.